Apparent mineralocorticoid excess syndrome in a Brazilian boy caused by the homozygous missense mutation p.R186C in the HSD11B2 gene

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 52, Issue 8, 2008, Pages 1277-1281

  Coeli, Fernanda Borchers ^a   Ferraz, Lúcio Fábio Caldas ^a   De Lemos Marini, Sofia H V ^a   Rigatto, Sumara Zuanazi Pinto ^a   Belangero, Vera Maria Santoro ^a   Maricilda, Palandi De Mello ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Apparent mineralocorticoid excess; Deficiency of 11 hydroxysteroid dehydrogenase type 2; HSD11B2 gene; Hypertension; Mutations

Indexed keywords

EID: 58849136626     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302008000800012     Document Type: Article

References (33)

1. White PC, Mune T, Agarwal AK. 11beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev. 1997;18(1):135-56.
2. New MI, Wilson RC. Steroid disorders in children: congenital adrenal hyperplasia and apparent mineralocorticoid excess. Proc Natl Acad Sci USA. 1999;96(22):12790-7.
3. Luft FC. Mendelian forms of human hypertension and mechanisms of disease. Clin Med Res. 2003;1(4):291-300.
4. Krozowski Z. The 11beta-hydroxysteroid dehydrogenases: functions and physiological effects. Mol Cell Endocrinol 1999;151(1-2): 121-7.
5. Krozowski ZS, Funder JW. Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc Natl Acad Sci USA. 1983;80(19): 6056-60.
6. Edwards C, Stewart P, Burt D, Brett L, Mclntyre M, Sutanto W, et al. Localisation of 11b-hydroxysteroid dehydrogenase: tissue specific protector of the mineralocorticoid receptor. Lancet. 1988;2(8618):986-9.
7. Krozowski ZS, Provencher PH, Smith RE, Obeyesekere VR, Mercer WR, Albiston AL. Isozymes of 11 beta-hydroxysteroid dehydrogenase: which enzyme endows mineralocorticoid specificity? Steroids. 1994;59(2):116-20.
8. Moore CC, Mellon SH, Murai J, Siiteri PK, Miller WL Structure and function of the hepatic form of 11b-hydroxysteroid dehydrogenase in the squirrel monkey, an animal model of glucocorticoid resistance. Endocrinology. 1993;133(1): 368-75.
9. Stewart PM, Murry BA, Mason Jl. Human kidney 11β-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform. J Clin Endocrinol Metab. 1994;79(2):480-4.
10. Rusvai E, Naray-Fejes-Toth A. A new isoform of 11b-hydroxysteroid dehydrogenase in aldosterone target cells. J Biol Chem. 1993;268(15):10717-20.
11. Agarwal AK, Rogerson FM, Mune T, White PC. Gene structure and chromosomal localization of the human HSD11K gene encoding the kidney (type 2) isozyme of 11 beta-hydroxysteroid dehydrogenase. Genomics. 1995;29f1): 195-9.
12. Mune T, Rogerson FM, Nikkilä H, Agarwal AK, White PC. Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Nat Genet. 1995;10(4):394-9.
13. Li A, Tedde R, Krozowski ZS, Pala A, Li KX, Shackleton CH, et al. Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess. Am J Hum Genet. 1998;63(2):370-9.
14. New Ml, Geller DS, Fallo F, Wilson RC. Monogenic low renin hypertension. Trends Endocrinol Metab. 2005;16(3):92-7.
15. Stewart PM, Krozowski ZS, Gupta A, Milford DV, Howie AJ, Sheppard MC, Whorwood CB. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 beta-hydroxysteroid dehydrogenase type 2 gene. Lancet. 1996;347(8994):88-91.
16. Dave-Sharma S, Wilson RC, Harbison MD, Newfield R, Azar MR, Krozowski ZS, et al. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J Clin Endocrin Metab. 1998;83(7):2244-54.
17. Ugrasbul F, Wiens T, Rubinstein P, New Ml, Wilson RC. Prevalence of mild apparent mineralocorticoid excess in Mennonites. J Clin Endocrinol Metab. 1999;84(12):4735-8.
18. Wilson RC, Dave-Sharma S, Wei JQ, Obeyesekere VR, Li K, Ferrari P, et al. A genetic defect resulting in mild low-renin hypertension. Proc Natl Acad Sci USA. 1998;95(17):10200-5.
19. Lavery GG, Ronconi V, Draper N, Rabbitt EH, Lyons V, Chapman KE, et al. Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene. Hypertension. 2003;42(2): 123-9.
20. Inada M, Iwasaki K, Imai C, Hashimoto S. Two elderly patients with mineralocorticoid excess due to 11 beta-hydroxysteroid dehydrogenase type 2 (11 beta-HSD2) impairment. Intern Med. 2008;47(7):631-6.
21. Nunez BS, Rogerson FM, Mune T, Igarashi Y, Nakagawa Y, Phillipov G, et al. Mutants of 11 beta-hydroxysteroid dehydrogenase (11-HSD2) with partial activity: improved correlations between genotype and biochemical phenotype in apparent mineralocorticoid excess. Hypertension. 1999;34(4 Pt 1):638-42.
22. Sambrook J, Fristsch EF, Maniatis TE. In: Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Press, Cold Spring Harbor, NY, USA. 1989.
23. Wilson RC, Harbison MD, Krozowski ZS, Funder JW, Shackleton CH, Hanauske-Abel HM, et al. Several homozygous mutations in the gene for 11 beta-hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab. 1995;80(11):3145-50.
24. Ferrari P, Obeyesekere VR, Li K, Wilson RC, New Ml, Funder JW, Krozowski ZS. Point mutations abolish 11 beta-hydroxysteroid dehydrogenase type II activity in three families with the congenital syndrome of apparent mineralocorticoid excess. Mol Cell Endocrinol. 1996;119(1):21-4.
25. Wilson RC, Nimkarn S, New Ml. Apparent mineralocorticoid excess. Trends Endocrinol Metab. 2001 12(3):104-11.
26. Quinkler M, Bappal B, Draper N, Atterbury AJ, Lavery GG, Walker EA, et al. Molecular basis for the apparent mineralocorticoid excess syndrome in the Oman population. Mol Cell Endocrinol. 2004;217(1-2):143-9.
27. Kamide K, Kokubo Y, Hanada H, Nagura J, Yang J, Takiuchi S, et al. Genetic variations of HSD11B2 in hypertensive patients and in the general population, six rare missense/frameshift mutations. Hypertens Res. 2006;29(4):243-52.
28. Morineau G, Sulmont V, Salomon R, Fiquet-Kempf B, Jeunamaitre X, Nicod J, Ferrari P. Apparent mineralocorticoid excess: report of six new cases and extensive personal experience. J Am Soc Nephrol. 2006;17(11):3176-84.
29. Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SD. Color and genomic ancestry in Brazilians. Proc Natl Acad Sci USA. 2003;100(1): 177-82.
30. Ollila J, Lappalainen I, Vihinen M. Sequence specificity in CpG mutation hotspots. FEBS Lett. 1996;396(2-3):119-22.
31. el Antri S, Mauffret O, Monnot M, Lescot E, Convert O, Fermandjian S. Structural deviations at CpG provide a plausible explanation for the high frequency of mutation at this site. Phosphorus nuclear magnetic resonance and circular dichroism studies. J Mol Biol. 1993;230(2):373-8.
32. Rogoff D, Smolenicka Z, Bergadá I, Vallejo G, Barontini M, Heinrich JJ, Ferrari P. The codon 213 of the 11 beta-hydroxysteroid dehydrogenase type 2 gene is a hot spot for mutations in apparent mineralocorticoid excess. J Clin Endocrinol Metab. 1998;83(12):4391-3.
33. Li A, Li KX, Marui S, Krozowski ZS, Batista MC, Whorwood CB, et al. Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state. J Hypertens. 1997;15(12 Pt 1):1397-402.